XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2022 $ 8,598 $ 57 $ 27,688 $ (12,975) $ (2,838) $ (4,128) $ 7,804 $ 794
Beginning balance, shares at Dec. 31, 2022   1,217            
Net Income (loss) (1,159)     (1,092)     (1,092) (68)
Other comprehensive income (loss) 92       161   161 (69)
Issuance of Shares, shares   10            
Stock-based compensation expense 62   62       62  
Ending balance at Jun. 30, 2023 7,592 $ 57 27,748 (14,066) (2,677) (4,128) 6,936 656
Ending balance, shares at Jun. 30, 2023   1,227            
Beginning balance at Mar. 31, 2023 8,504 $ 57 27,719 (13,194) (2,701) (4,128) 7,752 751
Beginning balance, shares at Mar. 31, 2023   1,226            
Net Income (loss) (906)     (872)     (872) (35)
Other comprehensive income (loss) (35)       25   25 (60)
Issuance of Shares, shares   1            
Stock-based compensation expense 30   30       30  
Ending balance at Jun. 30, 2023 7,592 $ 57 27,748 (14,066) (2,677) (4,128) 6,936 656
Ending balance, shares at Jun. 30, 2023   1,227            
Beginning balance at Dec. 31, 2023 8,126 $ 57 27,807 (13,534) (2,697) (4,128) 7,506 620
Beginning balance, shares at Dec. 31, 2023   1,227            
Net Income (loss) (1,294)     (985)     (985) (309)
Other comprehensive income (loss) (255)       (181)   (181) (74)
Issuance of Shares, value 1 $ 1         1  
Issuance of Shares, shares   12            
Stock-based compensation expense 60   60       60  
Proceeds from exercise of options 6   6       6  
Dividend to non-controlling interests (18)             (18)
Purchase of shares from non-controlling interests (64)   (45)   (3)   (48) (16)
Ending balance at Jun. 30, 2024 6,563 $ 58 27,829 (14,519) (2,881) (4,128) 6,359 204
Ending balance, shares at Jun. 30, 2024   1,239            
Beginning balance at Mar. 31, 2024 7,543 $ 58 27,796 (13,673) (2,775) (4,128) 7,278 265
Beginning balance, shares at Mar. 31, 2024   1,238            
Net Income (loss) (874)     (846)     (846) (29)
Other comprehensive income (loss) (138)       (106)   (106) (32)
Stock-based compensation expense 32   32       32  
Ending balance at Jun. 30, 2024 $ 6,563 $ 58 $ 27,829 $ (14,519) $ (2,881) $ (4,128) $ 6,359 $ 204
Ending balance, shares at Jun. 30, 2024   1,239